Core Insights - Shijiazhuang Pharmaceutical Group's new drug SYH2070 injection has received clinical trial approval for treating hyperlipidemia, marking a significant milestone in the cardiovascular drug sector [1][3][12] - The company has achieved a total of 16 new drug approvals this year, including two cardiovascular drugs, SYH2070 and SYH2068 injections [1][6][9] Drug Development and Approvals - SYH2070 injection is an innovative drug targeting ANGPTL3 and has received multiple approvals, including from the China NMPA and the US FDA, making it the first ANGPTL3 siRNA drug approved in both China and the US [3][12] - In 2024, the total sales of cardiovascular drugs in hospitals are projected to exceed 100 billion yuan [4] - Shijiazhuang Pharmaceutical has a total of 9 cardiovascular drugs approved for clinical use, showcasing its strong pipeline in this therapeutic area [6][9] Financial and R&D Investment - The company invested 2.683 billion yuan in R&D in the first half of 2025, a 5.5% increase year-on-year, representing 26.2% of its revenue from traditional Chinese medicine [12]
石药集团26亿投资：SYH2070中美双过批，16款1类新药临床推进！